Shopping Cart
Specialist article · PRP & extracellular vesicles
Updated: 4 September 2026
Reading time ≈ 15 min
PRP exosomes Platelet-derived exosomes, EVs and PRF in scientific context
“PRP exosomes” and “platelet-derived exosomes” are increasingly used in research, professional education and product communication. Scientifically, however, the terminology is often too imprecise. This article distinguishes platelet-derived extracellular vesicles (pEVs), PRP-derived EVs, liquid PRF and isolated EV preparations, reviews human and preclinical evidence, and explains why manufacturing, characterization and regulatory status must come before any efficacy claim.
Status at a glance
As of 08 / 2026Terminology
EV rather than blanket “exosome”
MISEV2023 recommends operational EV terminology when biogenesis has not been demonstrated. [1]
Human evidence
Early clinical phase
A randomized phase I safety study exists for allogeneic platelet-derived EVs; it did not show an efficacy advantage. [2]
EU / Germany
Case-by-case classification
EV products cannot be assigned to one regulatory category as a group. Origin, modification, manufacturing and intended purpose are decisive. [4][5]
EU cosmetics
Human origin is critical
Annex II of the EU Cosmetics Regulation lists cells, tissues and products of human origin as prohibited ingredients. [6]
Key points
- “PRP exosome” and “platelet-derived exosome” are often umbrella terms. Without evidence of an endosomal biogenesis pathway, “extracellular vesicle” is the more precise term.
- PRP preparations may already contain EVs. Platelets can release additional EVs upon activation. An isolated or enriched EV fraction is nevertheless not the same as conventional PRP.
- Source matters. Platelet-/PRP-EVs, MSC-EVs and cosmetically marketed “exosomes” must not be pooled scientifically.
- Human data exist. A phase I study of allogeneic platelet-derived EVs primarily assessed safety; robust clinical efficacy evidence is still lacking.
- MISEV is a characterization framework, not a quality seal. Particle count alone proves neither EV identity nor purity.
- Regulatory status comes before the claim. Medicinal-product, ATMP, cosmetics and advertising rules depend on the specific product and use context.
01
Why “exosome” is not automatically the correct term
Extracellular vesicles (EVs) are membrane-enclosed particles released by cells. “Exosome”, by contrast, refers to a particular biogenesis via the endosomal system. In a finished preparation, this route of origin often cannot be demonstrated unambiguously. MISEV2023 therefore recommends preferential use of operational terms such as small EV, marker-defined EVs or EVs from a named cell of origin. [1]
In the PRP context, terms such as platelet-derived extracellular vesicles (platelet-derived EVs, pEVs), or PRP-derived EVs when the material is actually obtained from a PRP fraction, are more precise. The widely used term “platelet-derived exosomes” can be useful as a search and literature term, but should not automatically be understood as a biogenetically confirmed exosome classification. The often-cited size range of 30–150 nm is not sufficient to classify a particle as an exosome.
Terminology in the literature
Older and current papers sometimes continue to use “exosome” as an umbrella term. When evaluating a study, the actual isolation and characterization methods should therefore be examined rather than relying on the wording of the title.
02
Why platelet-derived exosomes are receiving more attention
The term platelet-derived exosomes is appearing more frequently in reviews, dermatology publications and professional education. The underlying question is how much of PRP's biological signaling is mediated not only by freely soluble growth factors but also by extracellular vesicles released from platelets. A dermatology review of PRP-derived EVs mainly describes preclinical indications in wound healing; for hair growth and skin rejuvenation, clinical data remain scarce and methods for isolation, activation and delivery are not standardized. [19]
A 2026 PRP review explicitly places platelet-derived EVs within the broader biology of PRP while emphasizing that PRP is not a uniform biological product. Platelet concentration, leukocyte content, activation, fibrin architecture and preparation can alter biological composition. [20]
Important for search terminology
Greater visibility of the term “platelet-derived exosomes” does not mean that a new standardized treatment class has emerged. Cell source, manufacturing process, EV characterization and level of evidence remain decisive for scientific interpretation.
03
PRP may contain EVs – an EV fraction is still a different preparation
Platelets may carry circulating EVs and can release additional extracellular vesicles upon activation. PRP preparations may therefore contain heterogeneous EV populations in addition to soluble proteins, cytokines and other blood components. Quantity and composition depend, among other factors, on blood collection, anticoagulant, time to processing, temperature, centrifugation and activation conditions. A uniform “exosome dose” for PRP cannot be derived from this.
This does not make “PRP” and “isolated PRP-EVs” interchangeable. Once a vesicle fraction is deliberately separated, concentrated, purified or formulated, its composition, dose definition, quality control and potentially its regulatory status change. Results obtained with conventional PRP are therefore not evidence of efficacy for an EV concentrate, and vice versa.
| Term | Source | What it may mean | Transferability |
|---|---|---|---|
| PRP | Autologous blood | Platelet-rich plasma fraction with platelets, soluble factors and – depending on preanalytics/activation – EVs | Do not equate with isolated EVs |
| Liquid PRF / i-PRF | Autologous blood, typically without added anticoagulant | Liquid fibrin-rich fraction before complete clotting; composition depends on protocol | Distinct blood preparation, not synonymous with PRP or an EV concentrate |
| PRP-derived EVs | From a PRP fraction | Separated or enriched EV population; quality depends on method | Transfer only with comparable manufacturing |
| Platelet-derived EVs | Platelets / platelet concentrate | EVs from activated platelets; may be allogeneic or autologous | Not automatically “PRP exosomes” |
| MSC-/adipose-derived EVs | Stromal cells / adipose tissue | Different cellular source, cargo profile and manufacturing process | Do not transfer to PRP-EVs |
| “Exosome cosmetic” | Varies by product | Marketing term; source and particle identity require separate verification | Not a scientific product class |
PRP, PRF and EVs are not stages of development
PRP and liquid PRF are different autologous blood preparations. An isolated or enriched platelet-derived EV fraction requires additional processing and characterization. Standard PRP or PRF centrifugation is therefore not equivalent to validated exosome or EV isolation. Research on PRF-derived EVs exists, but clinical translation is also at an early stage. [21]
04
What an EV data sheet should actually demonstrate
MISEV2023 does not define a single “purity certificate”. The core requirement is transparent characterization using complementary methods: how the starting material was defined, how EVs were enriched, how abundance was estimated, which EV-associated components were detected and how strongly non-vesicular co-isolates are represented. [1]
A robust assessment framework
- Starting material and preanalytics: source, donor/patient context, anticoagulant, storage, time to processing and activation.
- Separation and concentration: e.g. SEC, density gradient, ultracentrifugation, filtration or affinity methods, including relevant process parameters.
- Abundance: particle measurement plus complementary protein/lipid measurements, with method, detection limit and measurement conditions.
- EV-associated markers: positive markers from different compartments and appropriate controls.
- Co-isolates: especially albumin, lipoproteins and other non-vesicular particles in plasma.
- Orthogonal confirmation: depending on the question, imaging or a second methodologically independent characterization approach.
- For clinical development additionally: sterility, endotoxin, identity, potency/function assay, stability and batch consistency.
Important
An NTA particle count is not an EV-specific cell count. Light-scattering particle measurements can also detect non-vesicular particles. The particle-to-protein ratio can provide context, but it is not a universal stand-alone purity measure.
05
Where the evidence really stands in 2026
Clinical development has begun, but it is far less advanced than many marketing texts imply. A key distinction is between platelet-derived EVs in general and EVs specifically obtained from PRP.
In 2023, a randomized, double-blind, placebo-controlled phase I study of allogeneic EVs obtained from activated platelets was published. Its primary focus was safety and tolerability in healthy adults. The studied single dose was well tolerated; wound-closure time did not differ between treated and untreated wounds. This is an important human safety data set, but not a clinical efficacy demonstration. [2]
Conflict-of-interest information is also relevant to interpretation: all authors of this phase I paper were employed by the developer of the investigated preparation or received financial support from it, and several authors were shareholders. This does not invalidate the study, but it should remain visible when weighting an early developer-associated data set. [2]
More recent reviews confirm growing research interest but do not fundamentally change the level of clinical evidence. Dermatologic applications still rely largely on preclinical data and face technical standardization problems; a 2026 review also explicitly emphasizes heterogeneity among PRP, PRF and PRP-derived EVs. [19][20]
Translational status of platelet- / PRP-derived EVs
The bars indicate the highest reliably documented evidence level for each field, not the magnitude of a treatment effect.
01Mechanism / cell model
02Animal model
03Human safety / early clinical
04Controlled efficacy
05Marketing authorization
Wound healing · platelet-derived EV
Human phase I safety study; no difference in wound-closure time at the investigated single dose. [2]
Cartilage / joint
PRP-EVs in preclinical defect models, partly combined with scaffolds. [13]
Tendon / rotator cuff
Animal study using PRP-EVs in fibrin gel; no human efficacy data. [14]
CNS / spinal cord
Preclinical data after spinal-cord injury; not transferable to an established human treatment. [15]
Aesthetic skin / hair
Human studies using “exosomes” frequently involve other cellular sources; they are not evidence for PRP- or platelet-derived EVs.
How to read this: “Human study available” does not mean “efficacy proven”. Published human evidence for platelet-derived EVs is currently primarily safety-oriented; controlled, indication-specific efficacy evidence remains outstanding.
What is happening clinically with “PRP-derived EVs”
Clinical programs for PRP-derived “exosomes” have now been registered. One example is NCT07124871, a single-arm feasibility study in erectile dysfunction; the registry entry currently reports no results. A trial registry shows development activity, but does not replace a publication or efficacy evidence. [16]
A 2026 study in diabetic foot ulcers is also important for interpretation: patients were treated with PRP, while isolated PRP-EVs were analyzed to correlate microRNA signatures with healing outcomes. This is biomarker/mechanistic research within PRP treatment, not an EV therapy trial. [17]
06
Safety: biologically active does not automatically mean clinically safe
Platelet-derived EVs carry membrane lipids and proteins that may participate in coagulation. Various EV populations have been described as supporting thrombin generation, with phosphatidylserine playing an important role. [18] This is first and foremost a biological property. Its clinical relevance depends on the preparation, dose, purity, route of administration and patient context.
Other issues must be addressed separately in every clinical development program: sterility and endotoxin, non-vesicular co-isolates, immunogenicity of allogeneic material, batch consistency, stability, traceability and a mechanism-appropriate potency assay.
FDA safety notice
Since 2019, the FDA has stated that there are no FDA-approved exosome products in the United States and has reported serious adverse events following the use of unapproved products. US classification cannot be transferred one-to-one to Europe, but it illustrates why “cell-free” is not a substitute for product quality and regulatory assessment. [3]
07
Legal framework in Germany and the EU: no one-word answer
PRP and medicinal-product law
The German Medicinal Products Act (AMG) defines blood preparations as medicinal products that are or contain blood, plasma or serum preparations obtained from blood, blood components or preparations made from blood components. [7] Whether a specific PRP procedure and its manufacture require authorization or notification depends on the setting and statutory exemptions. Section 13 AMG includes, among other provisions, an exemption for patient-specific manufacture under the direct professional responsibility of a person authorized to practise medicine. [8]
In 2024, the Bavarian Higher Administrative Court ruled in proceedings involving non-medical practitioners that the PRP autologous plasma procedure described there also fell under the physician reservation in Section 7(2) TFG. The ruling is important but should not be detached from its specific facts and generalized to every physician-performed PRP procedure. [10]
What changes with an isolated EV fraction?
A further processed vesicle fraction requires a separate regulatory assessment. Section 21 AMG generally governs marketing authorization for finished medicinal products before they are placed on the market and also contains statutory exemptions. [9] The statement “EV isolation automatically always triggers a particular authorization requirement” would therefore be too broad. Product type, extent of manufacturing, autologous/allogeneic origin, supply/placing on the market, modification and intended purpose must be assessed case by case.
ATMP: neither a blanket yes nor a blanket no
The regulatory discussion changed in 2025/2026. The current EMA guideline on investigational ATMPs has applied since 1 July 2025. A regulatory analysis published in 2026 places non-substantially modified cell-derived EVs outside the current ATMP definition; more extensively modified or loaded EVs may be assessed differently depending on the product concept. [4][5] A safe wording for shop or practice content is therefore: assess ATMP status product by product; do not infer it from the word “exosome”.
| Topic | Careful wording | What to avoid |
|---|---|---|
| EU market access | Assess product-specific medicinal-product classification and any required authorization/approval | “Exosomes can be used freely” |
| ATMP | Depends on product, modification and regulatory classification | “All exosomes are ATMPs” or “EVs are never ATMPs” |
| Cosmetics | Consider Annex II, entry 416, for ingredients of human origin | Treat human-derived EVs as ordinary cosmetic raw materials |
| USA | FDA: no approved exosome product; assess US rules separately | Transfer US status to EU law |
Legal framework provided only as editorial professional orientation; specific products and manufacturing processes require individual assessment. [3][4][6][7–10]
08
Which statements about PRP exosomes are scientifically supportable
On a commercial website, it is not enough to qualify individual sentences with “may” or “possibly”. The overall impression matters. Section 3 of the German Heilmittelwerbegesetz (HWG) prohibits misleading advertising, particularly where therapeutic effects are attributed without sufficient evidence. Section 3a HWG prohibits advertising for medicinal products that require authorization but are not authorized. [11]
Mechanisms, animal models, human safety data and clinical efficacy should therefore remain strictly separated in language. A disclaimer at the end cannot neutralize an earlier excessive healing or superiority claim.
| Too strong / misleading | More scientifically precise |
|---|---|
| ✗ avoid “PRP exosomes are revolutionizing regenerative medicine.” | ✓ better “Platelet-derived EVs are being investigated as possible mediators of biological PRP signaling.” |
| ✗ avoid “The next generation after PRP.” | ✓ better “A research approach that specifically characterizes or enriches EVs from platelets or PRP.” |
| ✗ avoid “Exosomes regenerate cartilage.” | ✓ better “Effects after PRP-EV administration have been described in preclinical cartilage-defect models; clinical transferability remains open.” |
| ✗ avoid “Safe and without side effects.” | ✓ better “A phase I study of one specific allogeneic pEV preparation primarily assessed safety; this cannot establish a general safety profile for other EV products.” |
| ✗ avoid Human MSC-EV study cited as evidence for “PRP exosomes”. | ✓ better Explicitly name cell source, manufacturing process and preparation in every evidence statement. |
09
What can reasonably be concluded from current research
The useful question is not whether EVs “work”, but which vesicle population, at what dose, from what source, manufactured by which process and assessed against which biological endpoint was studied. That is where the scientific work currently lies.
EV research is particularly relevant to PRP because it may help explain the known variability of blood preparations. The 2026 data on microRNA patterns in PRP-EVs in diabetic foot ulcers illustrate how EVs can be investigated as biomarkers of PRP composition and treatment response without turning them into a separate EV treatment. [17]
For interpretation
The most robust current value of EV research in the PRP context is to improve understanding of biological mechanisms, preparation variability and quality characteristics. It does not yet establish an independent EV therapy or clinical superiority over conventional PRP.
10
Conclusion
Platelet-derived and PRP-derived extracellular vesicles are a relevant research field within PRP biology. The evidence now extends beyond cell and animal models: a controlled phase I human study exists for one specific allogeneic platelet-derived EV preparation. It provides safety data, but no evidence of clinical superiority or a therapeutic effect in a disease.
For practice and product communication, a clear line remains appropriate: state the cell source, do not generalize the preparation or manufacturing process, characterize in line with MISEV, make the study level visible and make regulatory statements only for the specific product. “Exosome” may appear as a search term, but it should not serve as a blanket promise of quality or efficacy.
FAQ
Frequently asked questions about PRP exosomes and EVs
What are “PRP exosomes” in scientifically precise terms?
They usually refer to a population of extracellular vesicles obtained from PRP or activated platelets. The term “exosome” technically implies a specific biogenetic origin. If this has not been demonstrated, MISEV2023 recommends the broader term extracellular vesicles (EVs).
Does conventional PRP already contain extracellular vesicles?
PRP preparations may contain extracellular vesicles, and activated platelets can release additional EVs. Quantity and composition depend on preanalytics, preparation and activation. An isolated or concentrated EV preparation is nevertheless not equivalent to conventional PRP.
Are there human studies of platelet-derived EVs?
Yes. A randomized, double-blind, placebo-controlled phase I study of allogeneic platelet-derived EVs in healthy adults was published in 2023. The primary endpoint was safety; wound-closure time did not differ at the investigated single dose. This does not establish clinical efficacy in disease.
Is there robust efficacy evidence for PRP-derived EVs?
Human evidence for specific PRP-derived EV therapies remains very early. Registered clinical programs exist, while much of the frequently cited evidence comes from animal models, mechanistic studies or other EV sources. A registry entry is not evidence of efficacy.
Are extracellular vesicles automatically ATMPs in Europe?
No. A blanket classification is not appropriate. Regulatory status depends, among other factors, on source, modification, manufacturing process and intended purpose. Product-specific assessment is required.
What should a serious EV data sheet contain?
At minimum, a traceable description of starting material and preanalytics, separation, particle/abundance measurement with methods, EV-associated markers, controls for non-vesicular co-isolates and, in clinical development, sterility, endotoxin, stability and batch data. A single particle count or marker is not sufficient.
Can EVs of human origin be used as cosmetic ingredients?
Annex II of the EU Cosmetics Regulation lists “cells, tissues or products of human origin” as prohibited ingredients in cosmetic products. This prohibition is directly relevant to EVs obtained from human material; the specific product classification should be assessed before marketing.
What are platelet-derived exosomes?
The term is frequently used for small extracellular vesicles released by platelets. Scientifically, “platelet-derived extracellular vesicles” is usually more precise unless endosomal biogenesis has been clearly demonstrated.
Are platelet-derived exosomes the same as PRP?
No. PRP is a complex autologous blood preparation containing platelets, soluble factors and, depending on manufacture and activation, EVs. A deliberately isolated or enriched EV fraction is a differently characterized preparation.
What is the difference between PRP, liquid PRF and platelet-derived EVs?
PRP and liquid PRF are different autologous blood preparations with their own fibrin, cellular and activation characteristics. Platelet-derived EVs are a defined vesicle population or EV fraction that requires additional separation and characterization. The terms are not interchangeable.
Can standard PRP centrifugation isolate exosomes?
No. Standard PRP preparation can influence the composition of the blood preparation and the EVs it contains, but it is not a validated exosome or EV isolation procedure. Targeted EV enrichment or purification requires additional separation and characterization steps.
Q
Sources and legal references
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. (2024): Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles 13:e12404. DOI 10.1002/jev2.12404
- Johnson J, Law SQK, Shojaee M, et al. (2023): First-in-human clinical trial of allogeneic, platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing. J Extracell Vesicles 12:e12332. DOI 10.1002/jev2.12332
- U.S. Food and Drug Administration (2019): Public Safety Notification on Exosome Products, 06.12.2019.
- European Medicines Agency (2025): Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. EMA/CAT/22473/2025; effective since 01.07.2025
- Limongi T, et al. (2026): Regulatory Challenges and Opportunities for Cell-Derived Extracellular Vesicles in Pharmaceutical Development: A European and Global Perspective. J Extracell Vesicles. DOI 10.1002/jev2.70332
- Regulation (EC) No 1223/2009 on cosmetic products: Annex II, entry 416 “Cells, tissues or products of human origin”; current EU list of prohibited substances.
- German Medicinal Products Act (AMG), Section 4(2): Definition of blood preparations.
- German Medicinal Products Act (AMG), Section 13: Manufacturing authorization and statutory exemptions, including patient-specific manufacture under direct professional responsibility.
- German Medicinal Products Act (AMG), Section 21: Marketing authorization requirement for finished medicinal products and statutory exemptions.
- German Transfusion Act (TFG), Section 7(2); Bavarian Higher Administrative Court, 28.08.2024 – 20 BV 23.1807 / 20 BV 23.1808: Physician reservation for blood collection; decision in the context of autologous blood procedures by non-medical practitioners.
- German Heilmittelwerbegesetz (HWG), Sections 3 and 3a: Prohibition of misleading advertising and advertising for medicinal products that require authorization but are not authorized.
- Xu Y, Lin Z, He L, et al. (2021): Platelet-Rich Plasma-Derived Exosomal USP15 Promotes Cutaneous Wound Healing via Deubiquitinating EIF4A1. Oxid Med Cell Longev. DOI 10.1155/2021/9674809
- Liu X, Chen R, Cui G, et al. (2024): Exosomes derived from platelet-rich plasma present a novel potential in repairing knee articular cartilage defect combined with cyclic peptide-modified β-TCP scaffold. J Orthop Surg Res. DOI 10.1186/s13018-024-05202-z
- Li M, Shi L, Chen X, et al. (2024): In-situ gelation of fibrin gel encapsulating platelet-rich plasma-derived exosomes promotes rotator cuff healing. Commun Biol 7:205. DOI 10.1038/s42003-024-05882-7
- Nie X, Liu Y, Yuan T, et al. (2024): Platelet-rich plasma-derived exosomes promote blood-spinal cord barrier repair and attenuate neuroinflammation after spinal cord injury. J Nanobiotechnology. DOI 10.1186/s12951-024-02737-5
- ClinicalTrials.gov: Platelet Rich Plasma-Derived Exosomes Therapy for Erectile Dysfunction. NCT07124871; registry last updated 15.08.2025, no results posted
- Tsai YC, Wu SY, Wu CJ, et al. (2026): Distinct microRNA signatures in Platelet-Rich Plasma-Derived extracellular vesicles predict healing outcomes in chronic diabetic foot ulcers. Diabetes Res Clin Pract 233:113142. DOI 10.1016/j.diabres.2026.113142
- Tripisciano C, Weiss R, Eichhorn T, et al. (2017): Different potential of extracellular vesicles to support thrombin generation: contributions of phosphatidylserine, tissue factor, and cellular origin. Sci Rep 7:6522. DOI 10.1038/s41598-017-03262-2
- Gupta AK, Wang T, Rapaport JA, Talukder M. (2025): Therapeutic Potential of Extracellular Vesicles (Exosomes) Derived From Platelet-Rich Plasma: A Literature Review. J Cosmet Dermatol 24:e16709. DOI 10.1111/jocd.16709
- Liao B, Sun Z, Huang L, Cheng B. (2026): Platelet-Rich Plasma: An Endogenous Bioregulatory Modulator Coordinating Soft Tissue Remodeling. Aesthetic Plast Surg 50(15):6290–6300. DOI 10.1007/s00266-026-06089-3
- Bıçakçıoğlu HA, Çolak G. (2026): Platelet-rich fibrin-derived extracellular vesicles: emerging biological mediators in periodontal regeneration. Odontology 114(3):1086–1098. DOI 10.1007/s10266-025-01275-2